Predicting disease progression after regional therapy for in-transit melanoma

JAMA Surgery

Volumn 148, Issue 6, 2013, Pages 493-498

  Lidsky, Michael E ^a   Turley, Ryan S ^a   Beasley, Georgia M ^a   Sharma, Ketan ^a   Tyler, Douglas S ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; MELPHALAN;

ACIDOSIS; ADULT; ADVANCED CANCER; AGED; ALKALOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DATA BASE; DRUG INFUSION; FEMALE; GROUPS BY AGE; HUMAN; HYPERTHERMIC ISOLATED LIMB INFUSION; HYPERTHERMIC THERAPY; ISOLATED LIMB INFUSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84879373648     PISSN: 21686254     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamasurg.2013.695     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29.
2. Balch C. Cutaneous melanoma. In: Balch C, ed. Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 1993:1612-1661.
3. Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of intransit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005; 12(8):587-596. (Pubitemid 41126088)
4. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
5. Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2011;213(2):306- 316.
6. Therasse P, Arbuck SG, Eisenhauer EA, et al; European Organization for Research and Treatment of Cancer; National Cancer Institute of the United States; National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205-216. (Pubitemid 30099779)
7. Trotti A, Colevas AD, Setser A, et al. CTCAE V3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-181. (Pubitemid 36962641)
8. Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15(8):2195- 2205.
9. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132(8):903- 907. (Pubitemid 27344144)
10. McMahon N, Cheng TY, Beasley GM, et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol. 2009;16(4):953-961.
11. Aloia TA, Grubbs E, Onaitis M, et al. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg. 2005;140(11): 1115-1120. (Pubitemid 41668683)
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J AmStat Assoc. 1958;53(282):457-481. doi:10.1080/01621459.1958. 10501452.
13. Grotz TE, Mansfield AS, Kottschade LA, et al. In-transit melanoma: an individualized approach. Oncology (Williston Park). 2011;25(14):1340-1348.
14. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2116. (Pubitemid 29318842)
15. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park). 1995;9(11):1149-1158; discussion 1163-1164, 1167-1168.
16. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17(9):2745-2751. (Pubitemid 29415231)
17. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
18. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517- 2526.
19. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208(5):706-715; discussion 715-717.
20. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008; 15(11):3003-3013.
21. Cornett WR, McCall LM, Petersen RP, et al; American College of Surgeons Oncology Group Trial Z0020. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24(25):4196-4201. (Pubitemid 46622299)
22. Di Filippo F, Calabrò A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer. 1989;63 (12):2551-2561. (Pubitemid 19152772)
23. Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR, Hart AA. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery. 1994;115(1):39-45. (Pubitemid 24039210)
24. Kroon BB, Van Geel AN, Benckhuijsen C, Wieberdink J. Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Anticancer Res. 1987;7(3, pt B):441-442. (Pubitemid 17151928)
25. Minor DR, Allen RE, Alberts D, Peng YM, Tardelli G, Hutchinson J. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer. 1985;55(11):2638-2644. (Pubitemid 15092151)
26. Skene AI, Bulman AS, Williams TR, Thomas JM, Westbury G. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg. 1990;77(7):765-767. (Pubitemid 20236115)
27. Sharma K, Beasely G, Turley R, et al. Patterns of Recurrence Following Complete Response to Regional Chemotherapy for In-Transit Melanoma. Ann Surg Oncol. 2012;19(8):2563-2571.
28. Lindnér P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002; 9(2):127-136. (Pubitemid 34259697)
29. Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg. 2007;245 (4):591-596. (Pubitemid 46555663)
30. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14(3):238-247. (Pubitemid 28146516)